Back to Treatments

Treatment

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir

1
Conditions
1
Trials
5,000
Participants
65%
Average Safety

Condition Evidence

Acute hepatitis C

1 trials · 5,000 participants

96% effectiveness · 65% safety
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir | DFDA